Interstitial Cystitis
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00056251 |
Recruitment Status :
Completed
First Posted : March 10, 2003
Last Update Posted : June 24, 2005
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Interstitial Cystitis | Procedure: H&P; ECG; Blood tests; voiding diary; Cystoscopy | Phase 2 |
RATIONALE:
Topical resiniferatoxin (RTX) administrated to the bladder may be effective in decreasing the symptoms associated with interstitial cystitis through its action on pain sensing neurons.
PURPOSE:
Randomized, double-blind, placebo-controlled, Phase 2 trial to determine the safety and efficacy of RTX in patients with interstitial cystitis.
Study Type : | Interventional (Clinical Trial) |
Enrollment : | 150 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double |
Primary Purpose: | Treatment |
Official Title: | A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of RTX Topical Solution in Patients With Interstitial Cystitis |
Study Start Date : | January 2003 |
Study Completion Date : | August 2003 |


Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 70 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- ≥ 18 years of age.
- Have IC that meets disease diagnostic criteria as defined by a history of the following:
- Cystoscopy/hydrodistension with a diagnosis of IC confirmed by findings of Hunner's ulcer or glomerulation
- Symptoms of bladder pain and urinary urgency for at least 6 months
- Urinary frequency while awake at least 8 times a day while awake
- Nocturia at least twice a night
- Symptoms not significantly relieved by antimicrobial agents, anticholinergic drugs, or antispasmodics
- Have IC that in the judgment of the investigator has been stable in the previous 30 days
- Have IC-related pain despite current therapy, defined as a score of 4 or greater [(on a scale from 0 (none) to 9 (severe)] on average over the past month and confirmed by the voiding diary collected at Visit 2
- Have at least one voided volume ≥ 75 cc in a 24 hour period, confirmed by the voiding diary collected at Visit 2
- Patients of childbearing potential must agree to use an acceptable form of contraception (oral contraceptives, intrauterine device or double barrier methods) from Visit 1 through Visit 6
- Provide signed informed consent
Exclusion Criteria:
- Currently pregnant or breastfeeding
- Presence of ulcers on the pre-treatment cystoscopy
- Intravesical therapy or bladder hydrodistention within the previous 60 days
- Initiation of pentosan polysulfate sodium (Elmiron®) within the previous 16 weeks
- Use of fentanyl patches, morphine sulfate, methadone or B&O supprettes within the previous 30 days.
- Previous augmentation cystoplasty, cystectomy or cystolysis, neurectomy (i.e., hypogastric nerve plexus ablation) or implanted peripheral nerve stimulator which has affected bladder function
- History of ureteral reflux. Patients with a history of childhood urinary tract infections, recurrent urinary tract infections as an adult (defined as >3 culture documented episodes within the previous 12 months), or pyelonephritis at any time must have a cystourethogram to rule out ureteral reflux.
- Evidence of renal impairment (creatinine > 2 times the upper limit of normal at Visit 1), hepatic impairment (AST or ALT > 3 times the upper limit of normal at Visit 1), clinically significant cardiovascular, respiratory, or psychiatric diseases
- Any condition that in the judgment of the investigator would interfere with the patient's ability to provide informed consent, comply with study instructions, place the patient at increased risk, or which might confound the interpretation of the study results
- Treatment with a drug or medical device that has not received regulatory approval within the previous 30 days
- Investigators, study staff and their immediate families. Immediate family is defined as current spouse, parent, natural or legally adopted child (including a stepchild living in the investigator's household), grandparent, or grandchild.
- Previously completed or withdrawn from this study
- Urinary tract or prostatic infection within the past 3 months before study entry
- Active genital herpes or vaginitis
- Urethral diverticulum
- Uterine, cervical, vaginal, or urethral cancer within the past 5 years before study entry
- History of cyclophosphamide or chemical cystitis, urinary tuberculosis or radiation cystitis
- History of bladder tumors (benign or malignant)

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00056251

Study Director: | Lyn Frumkin, M.D., Ph.D. | ICOS Corporation, (425) 415-5571, lfrumkin@icos.com |
ClinicalTrials.gov Identifier: | NCT00056251 |
Other Study ID Numbers: |
JIC01 |
First Posted: | March 10, 2003 Key Record Dates |
Last Update Posted: | June 24, 2005 |
Last Verified: | January 2004 |
Interstitial Cystitis Bladder |
Cystitis Cystitis, Interstitial Urinary Bladder Diseases Urologic Diseases |